Targeting hypoxia in the treatment of small cell lung cancer

Highlights • Hypoxia is prevalent in small cell lung cancer (SCLC) tumours and leads to cellular adaptations associated with aggressive tumours. • Many methods of targeting hypoxia for cancer therapy have been explored; however, this treatment remains relatively under-investigated for SCLC. • This r...

Full description

Saved in:

Bibliographic Details
Published in:	Lung cancer (Amsterdam, Netherlands) Vol. 86; no. 2; pp. 126 - 132
Main Authors:	Bryant, J.L, Meredith, S.L, Williams, K.J, White, A
Format:	Journal Article
Language:	English
Published:	Oxford Elsevier Ireland Ltd 01-11-2014 Elsevier
Subjects:	Acidosis Animals Antineoplastic Agents - therapeutic use Biological and medical sciences Bioreductive prodrugs Hematology, Oncology and Palliative Medicine HIF-1α Humans Hypoxia Hypoxia - drug therapy Hypoxia - metabolism Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Medical sciences Molecular Targeted Therapy Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Pneumology Pulmonary/Respiratory Resistance Small cell lung cancer Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - metabolism Targeted therapy Tumors Tumors of the respiratory system and mediastinum Resistance Bioreductive prodrugs Small cell lung cancer Targeted therapy Hypoxia HIF-1α Acidosis Lung disease Oxygen Targeting Respiratory disease Lung cancer Lung Acid base balance disorder Malignant tumor Metabolic disorder Treatment Targeted drug Bronchus disease Transcription factor HIF1 Small cell carcinoma Cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Highlights • Hypoxia is prevalent in small cell lung cancer (SCLC) tumours and leads to cellular adaptations associated with aggressive tumours. • Many methods of targeting hypoxia for cancer therapy have been explored; however, this treatment remains relatively under-investigated for SCLC. • This review highlights various treatment options available for targeting hypoxic cells within tumours and how these could be highly beneficial in the treatment of SCLC. • Treatment options include the use of bioreductive prodrugs as well as inhibiting pH-regulating enzymes upregulated under hypoxic conditions.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2014.08.003